← Leaderboards
Luke Joseph Peppone
University Of Rochester
$4,817,736
Attributed
$5,232,123
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $948.1K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,232,123 · 6
By mechanism
R01$3,365,488 · 2
K07$724,305 · 1
T32$621,581 · 1
R21$367,249 · 1
R03$153,500 · 1
Top collaborators
- Michelle C Janelsins2 shared
- Gary R Morrow2 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Steven R. Gill$10,593,235
- Tongtong Wu$1,063,472
- Jin Xiao$3,267,175
- Tracie L Miller$4,322,342
- Michelle C Janelsins$9,674,346
Others in their field
Top investigators on “Randomized”
- James Dennis Neaton · Northwestern University$305,243,252
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$292,521,996
- Lawrence Corey · Fred Hutchinson Cancer Center$292,521,996
- Marian Ewell · The Emmes Company, Llc$278,931,253
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$199,647,509
- Beth Baseler · Leidos Biomedical Research, Inc.$194,920,310
Research focus
RandomizedQuality Of LifeBaseDesignDoseBiologicalIncidenceRegimenMalignant NeoplasmsPlacebosPreventionCholecalciferolExercisePreventFractureProgramsDouble-Blind MethodBone HealthBone LossCancer PatientBisphosphonateCancer CenterEfficacy TestingBone Density
Grant awards (19)
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients$639,100
R01 · FY2025 · CA · contact PI
Clinical and Translational Cancer Control Research Training Program$280,631
T32 · FY2025 · CA
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients$607,140
R01 · FY2024 · CA · contact PI
Clinical and Translational Cancer Control Research Training Program$340,950
T32 · FY2024 · CA
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients$625,965
R01 · FY2023 · CA · contact PI
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients$635,824
R01 · FY2022 · CA · contact PI
Treatment of Refractory Nausea$215,985
R01 · FY2021 · CA · contact PI
Treatment of Refractory Nausea$215,985
R01 · FY2020 · CA · contact PI
Treatment of Refractory Nausea$209,504
R01 · FY2019 · CA · contact PI
Treatment of Refractory Nausea$215,985
R01 · FY2017 · CA · contact PI
Management of Cancer-Treatment-Induced Bone Loss$144,893
K07 · FY2017 · CA · contact PI
Management of Cancer-Treatment-Induced Bone Loss$144,893
K07 · FY2016 · CA · contact PI
High-dose Vitamin D Supplementation for ADT-induced Side Effects$166,931
R21 · FY2015 · CA · contact PI
Management of Cancer-Treatment-Induced Bone Loss$144,893
K07 · FY2015 · CA · contact PI
Feasibility of Omega-3 Supplementation for Cancer-related Fatigue$76,750
R03 · FY2015 · CA · contact PI
High-dose Vitamin D Supplementation for ADT-induced Side Effects$200,318
R21 · FY2014 · CA · contact PI
Management of Cancer-Treatment-Induced Bone Loss$144,893
K07 · FY2014 · CA · contact PI
Feasibility of Omega-3 Supplementation for Cancer-related Fatigue$76,750
R03 · FY2014 · CA · contact PI
Management of Cancer-Treatment-Induced Bone Loss$144,733
K07 · FY2013 · CA · contact PI